STEVENSON, Md., Dec. 28, 2016 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of Universal Health Services, Inc. (NYSE:UHS) (“Universal Health” or the “Company”) securities during the period between February 26, 2015 and December 7, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until February 21, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Universal Health securities during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Universal Health admitted patients based on its own financial considerations and not upon the medical necessity of the patient and would keep patients admitted until their insurance payments ran out in order to ensure the maximum payment for its services, Universal Health’s revenues from inpatient care relied on unsustainable practices, and the Company lacked effective internal control concerning its practices and policies of admitting patients.
According to the complaint, following a December 7, 2016 investigative story on Universal Health regarding its practices, the value of Universal Health shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Universal Health securities purchased on or after February 26, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking.
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 



